References 1 Curatolo P , Bombardieri R , Jozwiak S . Tuberous sclerosis . Lancet 2008 ; 372 ( 9639 ): 657 – 68 . 2 Curatolo P , Moavero R , de Vries PJ . Neurological and neuropsychiatric aspects of tuberous sclerosis complex . Lancet Neurol 2015 ; 14 ( 7 ): 733 – 45 . 3 Chu-Shore CJ et al . The natural history of epilepsy in tuberous sclerosis complex . Epilepsia 2010 ; 51 ( 7 ): 1236 – 41 . 4 Prabowo AS et al . Fetal brain lesions in tuberous sclerosis complex : TORC1 activation and inflammation . Brain Pathol 2013 ; 23 ( 1 ): 45 – 59 . 5 Crino PB . Molecular pathogenesis of tuber formation in tuberous sclerosis complex . J Child Neurol 2004 ; 19 ( 9 ): 716 – 25 . 6 Curatolo P . Mechanistic target of rapamycin ( mTOR ) in tuberous sclerosis complex-associated epilepsy . Pediatr Neurol 2015 ; 52 ( 3 ): 281 – 9 . 7 Curatolo P et al . mTOR |
dysregulation and tuberous sclerosis-related epilepsy . Expert Rev Neurother 2018 ; 18 ( 3 ): 185 – 201 . 8 Widjaja E et al . Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex . Epilepsy Res 2010 ; 89 ( 2-3 ): 246 – 53 . 9 Moavero R et al . White matter disruption is associated with persistent seizures in tuberous sclerosis complex . Epilepsy Behav 2016 ; 60:63 – 7 . 10 Chiron C et al . Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis . Epilepsy Res 1997 ; 26 ( 2 ): 389 – 95 . 11 Bombardieri R et al . Early control of seizures improves long-term outcome in children with tuberous sclerosis complex . Eur J Paediatr Neurol 2010 ; 14:146 – 9 . 12 Cusmai R et al . Long-term |
neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis . Epilepsy Behav 2011 ; 22 ( 4 ): 735 – 9 . 13 Zhang B et al . Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex . PLoS One 2013 ; 8 ( 2 ): e57445 . 14 Curatolo P et al . Management of epilepsy associated with tuberous sclerosis complex ( TSC ): clinical recommendations . Eur J Paediatr Neurol 2012 ; 16 ( 6 ): 582 – 6 . 15 Wu JY et al . Noninvasive testing , early surgery , and seizure freedom in tuberous sclerosis complex . Neurology 74 ( 5 ): 392 – 8 . 16 Zamponi N et al . Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis . Pediatr Neurol 2010 ; 43 ( 1 ): 29 – 34 . 17 McDaniel SS et al . The ketogenic diet inhibits the mammalian target of rapamycin ( mTOR ) pathway . Epilepsia |
2011 ; 52 ( 3 ): e7 – 11 . 18 Kossoff EH et al . Tuberous sclerosis complex and the ketogenic diet . Epilepsia 2005 ; 46 ( 10 ): 1684 – 6 . 19 Krueger DA et al . Everolimus treatment of refractory epilepsy in tuberous sclerosis complex . Ann Neurol 2013 ; 74 ( 5 ): 679 – 87 . 20 Krueger DA et al ., Long-term treatment of epilepsy with everolimus in tuberous sclerosis . Neurology 2016 ; 87 ( 23 ): 2408 – 15 . 21 Wiegand G et al . Everolimus in tuberous sclerosis patients with intractable epilepsy : a treatment option ? Eur J Paediatr Neurol 2013 ; 17 ( 6 ): 631 – 8 . 22 Cardamone M et al . Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex . J Pediatr 2014 ; 164 ( 5 ): 1195 – 200 . 23 Samueli S et al . Efficacy and safety of everolimus in children with TSC-associated |
epilepsy – Pilot data from an open single-center prospective study . Orphanet J Rare Dis 2016 ; 11 ( 1 ): 145 . 24 Overwater IE et al . Sirolimus for epilepsy in children with tuberous sclerosis complex : A randomized controlled trial . Neurology 2016 ; 87 ( 10 ): 1011 – 18 . 25 French JA et al . Adjunctive everolimus therapy for treatment-resistant focalonset seizures associated with tuberous sclerosis ( EXIST-3 ): a phase 3 , randomised , doubleblind , placebo-controlled study . Lancet 2016 ; 388 ( 10056 ): 2153 – 63 . 26 Jozwiak S et al . Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex . Eur J Paediatr Neurol 2011 ; 15 ( 5 ): 424 – 31 . |
120 |
||||
HHE 2018 | hospitalhealthcare . com |